Author(s): Bunck MC, Diamant M, Eliasson B, Cornr A, Shaginian RM,
Abstract Share this page
Abstract OBJECTIVE: To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. RESEARCH DESIGN AND METHODS: Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured. RESULTS: Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13\%, respectively. In addition, exenatide increased total adiponectin by 12\% and reduced high-sensitivity C-reactive protein by 61\%. Insulin glargine significantly reduced endothelin-1 by 7\%. These changes were statistically independent of the change in total body fat mass and body weight. CONCLUSIONS: Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.
This article was published in Diabetes Care
and referenced in Journal of Diabetes & Metabolism